Want to see GB:CIZ full AI Analyst Report?
Top Page
Cizzle Biotechnology Holdings PLC
(LSE:CIZ)
Select Model
Select Model
Rating:41Neutral
Price Target:
1.50 p
▲(0.00% Upside)
Action:Reiterated
Date:08/28/26
The score is driven down primarily by weak financial performance (pre-revenue, sustained losses and cash burn, and equity turning negative in 2025). Technicals also remain decisively bearish (below key moving averages with negative MACD). Valuation provides limited offset due to negative earnings and no dividend yield data.
Positive Factors
Focused Diagnostic Platform
A focused biomarker platform gives the company a clear scientific and commercial objective. If clinical validation and regulatory progress succeed, early-detection diagnostics could support durable demand and strategic partnering interest.
Negative Factors
Pre-Commercial Business
The absence of reported revenue shows that the diagnostic platform has not yet achieved commercial scale. Until validation, regulatory milestones, and customer adoption translate into sales, funding depends heavily on external capital or future partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Diagnostic Platform
A focused biomarker platform gives the company a clear scientific and commercial objective. If clinical validation and regulatory progress succeed, early-detection diagnostics could support durable demand and strategic partnering interest.
Read all positive factors
Cizzle Biotechnology Holdings PLC (CIZ) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£6.16M
Dividend YieldN/A
Average Volume (3M)3.12M
Price to Earnings (P/E)―
Beta (1Y)-0.66
Revenue GrowthN/A
EPS Growth69.64%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume5,449,519
30 Day Avg. Volume3,118,138
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model
Company Description
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzl...
How the Company Makes Money
Cizzle Biotechnology’s primary intended revenue model is to generate income from the commercialization of its lung-cancer diagnostic technology, typically through licensing and/or partnership arrangements with established diagnostics, laboratory, ...
Cizzle Biotechnology Holdings PLC Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -753.00K | -878.00K | -976.00K | -963.00K | -3.96M |
| Net Income | -691.00K | -2.17K | -1.72K | -910.00K | -3.92M |
Balance Sheet | |||||
| Total Assets | 245.00K | 492.00K | 1.69M | 2.79M | 1.16M |
| Cash, Cash Equivalents and Short-Term Investments | 116.00K | 387.00K | 1.56M | 478.00K | 875.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 585.00K | 410.00K | 186.00K | 145.00K | 218.00K |
| Stockholders Equity | -340.00K | 82.00K | 1.51M | 2.64M | 937.00K |
Cash Flow | |||||
| Free Cash Flow | -498.00K | -358.00K | -639.00K | -872.00K | -1.21M |
| Operating Cash Flow | -496.00K | -358.00K | -639.00K | -872.00K | -1.01M |
| Investing Cash Flow | -2.00K | 0.00 | 0.00 | -120.00K | -154.00K |
| Financing Cash Flow | 249.00K | 579.00K | 305.00K | 595.00K | 2.03M |
Cizzle Biotechnology Holdings PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £3.98M | -1.68 | -37.30% | ― | ― | 85.56% | |
46 Neutral | £5.94M | -1.52 | -52.92% | ― | 34.02% | -93.85% | |
45 Neutral | £4.18M | -3.61 | -83.53% | ― | ― | 93.02% | |
42 Neutral | £1.22M | -0.38 | -152.41% | ― | -70.77% | 60.39% | |
42 Neutral | £1.85M | -0.35 | -70.79% | ― | -36.97% | 62.76% | |
41 Neutral | £6.16M | -8.53 | 104.99% | ― | ― | 69.64% |
* Healthcare Sector Average
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.45
0.10
7.41%
GB:TCF
Evgen Pharma
0.19
-0.07
-26.00%
GB:FUM
Futura Medical
0.24
-9.74
-97.61%
GB:NFX
Nuformix Plc
0.17
0.04
35.25%
GB:OPTI
OptiBiotix Health
5.95
-4.30
-41.95%
GB:VAL
ValiRx plc
0.15
-0.61
-80.67%
Cizzle Biotechnology Holdings PLC Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cizzle expands U.S. lung cancer test access with new BioBridge lab deal
Positive
Aug 3, 2026
Cizzle Biotechnology’s North American licensee, Cizzle Bio Inc, has signed a strategic laboratory agreement with BioBridge Global’s BBG Advanced Therapies to offer the CIZ1B biomarker blood test for lung cancer through a CLIA-certified...
Business Operations and StrategyProduct-Related Announcements
Cizzle Biotechnology’s Lung Cancer Blood Test Enters Full Commercial Sales in Key Texas Markets
Positive
Jul 22, 2026
Cizzle Biotechnology’s North American partner Cizzle Bio Inc has begun full commercial sales of the CIZ1B biomarker blood test for lung cancer to licensed healthcare providers in the Dallas-Fort Worth and San Antonio metropolitan areas. Thes...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Cizzle Biotechnology Enters Commercial Phase With U.S. Lung Cancer Test Accreditation
Positive
Jul 15, 2026
Cizzle Biotechnology has entered a pivotal commercial phase after its CIZ1B blood test for early-stage lung cancer received CLIA accreditation for clinical use in the U.S., enabling routine ordering by licensed healthcare providers through OmniHea...
Business Operations and Strategy
Cizzle Biotechnology Appoints Zeus Capital as Sole Corporate Broker
Positive
Jun 30, 2026
Cizzle Biotechnology Holdings plc is a life sciences company specialising in a proprietary CIZ1B biomarker blood test for the early detection of lung cancer. Its non-invasive, cost-effective diagnostic is being rolled out through royalty-bearing l...
Financial DisclosuresPrivate Placements and FinancingShareholder Meetings
Cizzle Biotechnology shareholders back all AGM resolutions, expand board authorities
Positive
Jun 16, 2026
Cizzle Biotechnology Holdings reported that all resolutions at its latest annual general meeting were passed by a show of hands, with proxy votes showing overwhelming support across all motions. Shareholders approved the 2025 accounts and remunera...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Cizzle wins U.S. CLIA approval for CIZ1B early lung cancer blood test
Positive
Jun 16, 2026
Cizzle Biotechnology has secured CLIA accreditation in the U.S. for its proprietary CIZ1B biomarker blood test, enabling clinical use at OmniHealth Diagnostics in Dallas and allowing licensed U.S. healthcare providers to order the test. The lab-de...
Business Operations and StrategyProduct-Related Announcements
Cizzle Biotechnology Gains Key U.S. Patent for CIZ1B Lung Cancer Test
Positive
Jun 12, 2026
Cizzle Biotechnology has secured a key U.S. patent covering its core methods for measuring the CIZ1B lung cancer biomarker, adding to existing protection in Canada and Europe. The patent supports its North American licensee, Cizzle Bio Inc, as it ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.